Comment from Bharathi Kodali

COMMENT 1: REPEAT OBSERVATIONS REQUIRE A DISTINCT EVIDENTIARY STANDARD Gap: The draft applies the same response framework to all 483 observations regardless of whether the observation is new or has appeared before at the same or an affiliated site. A repeat observation is not the same compliance event as a first-occurrence observation. It is evidence that a prior CAPA failed. The guidance does not acknowledge that distinction. The guidance must reflect this operational reality. An establishment that genuinely closed a systemic failure can prove it. One that cannot provides FDA with an evidence-based signal for escalation. This protects patients by converting the response from a compliance performance into a compliance proof. COMMENT 2: ATTORNEY-CLIENT PRIVILEGE CONFLICT IS UNRESOLVED Gap: The draft requires disclosure of outside counsel identity and their role in preparing the 483 response. This requirement conflicts directly with attorney-client privilege. It has no resolution mechanism in the current draft. Unresolved privilege tension produces inconsistent responses across the industry. Inconsistency makes FDA's comparative assessment of remediation quality harder. That directly impairs the Agency's ability to identify establishments where escalation is warranted. COMMENT 3: EFFECTIVENESS CHECK STANDARD MUST BE TIERED AND OPERATIONALISED Gap: The draft states that effectiveness evaluations should 'go beyond routine sampling and testing.' This is an expectation without a method. There is no defined standard for what constitutes an adequate effectiveness check. Sophisticated firms design statistically valid prospective checks. Others confirm the action was taken with a single batch review. FDA receives both and has limited basis to distinguish them before the next inspection. The guidance's stated purpose is to help firms implement effective corrective actions. A risk-stratified, prospective effectiveness standard for critical findings is the only mechanism that converts that purpose into measurable patient outcomes. COMMENT 4: THE 15-DAY WINDOW CREATES A STRUCTURAL INEQUITY FOR FOREIGN ESTABLISHMENTS Gap: The draft applies the same 15-business-day response window to domestic and foreign establishments. Foreign establishments now represent the majority of FDA-regulated drug manufacturing globally. The same clock applied to fundamentally different operational realities produces unequal outcomes. A response submitted on day 14 by a foreign establishment that navigated genuine logistical complexity is more valuable to patient safety than one submitted on day 10 with full domestic infrastructure, if the quality of the investigation is equal. The guidance should be designed to produce the best substantive response from every establishment in the world. COMMENT 5: PRE-BUILT RESPONSE INFRASTRUCTURE SHOULD BE A QUALITY SYSTEM EXPECTATION Gap: The draft guidance is entirely reactive. It addresses how to respond after receiving a 483. It does not address whether establishments have the infrastructure to respond well before a 483 arrives. The establishments most likely to submit poor-quality responses are those without that infrastructure. They are also the most common source of the inadequate responses that motivated FDA to publish this guidance. The guidance's impact is largest where establishments need it most. Recommending pre-built infrastructure as a quality system expectation extends the guidance's reach from firms that already respond well to the firms where the patient safety gap is greatest. COMMENT 6: LONGITUDINAL 483 HISTORY ANALYSIS MUST BE A FORMALISED QUALITY FUNCTION Gap: The draft addresses how to respond to a 483. It does not address how establishments should use their own cumulative 483 history as a quality intelligence instrument. An establishment's inspection record is the most accurate predictor of what the next inspection will find. The guidance does not require establishments to use it. The guidance's ultimate measure of success is a downward trend in repeat observations and warning letters. Longitudinal 483 intelligence, formalised as a quality management function and cross-referenced against industry-wide patterns, is the mechanism that converts inspection history from a compliance record into a prevention instrument. Complete comment, with the gap, proposal is enclosed in the word document. Bharathi Kodali +491636881833 bharathi.kodali123@gmail.com